Overview

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Status:
RECRUITING
Trial end date:
2027-11-04
Target enrollment:
Participant gender:
Summary
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
dexamethasone acetate
exemestane
fludrocortisone acetate
Fulvestrant
Letrozole
Medroxyprogesterone Acetate
Megestrol Acetate
Tamoxifen